RxDoctor Payments Data

Savitha Susarla, DO

Family Medicine · Elgin, ILNPI 1518976323

Payments from drug & device makers

$9,214in general payments, 2019–2025

Across 391 payments — averaging $23.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Boehringer Ingelheim$732
  • Lilly USA, LLC$708
  • Amgen$507
  • Johnson & Johnson$466
  • plus $3K from 27 others

What the payments were for

  • Speaking & faculty fees$1,40815%
  • Travel & lodging$210%
  • Food & beverage$7,57882%
  • Education$2082%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,214 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$52,141
Medicare patients
125
Services billed
571

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$60,753
JardianceEmpagliflozin46$58,798
MounjaroTirzepatide36$37,693
EliquisApixaban39$29,938
FarxigaDapagliflozin Propanediol18$21,605
XareltoRivaroxaban19$14,151
Combivent RespimatIpratropium/Albuterol Sulfate14$9,087
Atorvastatin Calcium325$2,648
Memantine Hcl41$1,924
Losartan Potassium223$1,920
Albuterol Sulfate HfaAlbuterol Sulfate52$1,830
Levothyroxine Sodium187$1,774
Gabapentin86$1,577
Metformin Hcl142$1,358
Metoprolol Succinate85$1,356

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat$732$67,88560 claims
Novo NordiskOzempic$1,107$60,75349 claims
Lilly USA, LLCMounjaro$708$37,69336 claims
PfizerEliquis$300$29,93839 claims
AstraZenecaFarxiga$449$21,60518 claims
Johnson & JohnsonXarelto$466$14,15119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Elgin

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →